2021 NOSCM | New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
Overview
NA
Target Audience
NA
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Nicole Ianniello, PharmD
Date of Release
May 14th, 2025
-1762275636722.webp&w=3840&q=75)
-1755991489210.webp&w=3840&q=75)